

Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

| | | | URGEN | |
|--|--|-------------------------------------|------------------------|--|
| MEMBER INFORMATION | | | | |
| LAST NAME: | | FIRST NAME: | FIRST NAME: | |
| PHONE NUMBER: | | DATE OF BIRTH: | DATE OF BIRTH: | |
| STREET ADDRESS: | | | | |
| CITY: | | STATE: ZIP CC | DDE: | |
| PATIENT INSURANCE ID I | NUMBER: | | | |
| MALE FEMALE | HEIGHT (IN/CM): WE | EIGHT (LB/KG): ALLI | ERGIES: | |
| | ESCRIBER, YOU WILL NEED TO SUBMIT A PHI D K.COM/MEMBER/EXTERNAL/COMMERCIAL/CO | | | |
| | EPRESENTATIVE (IF APPLICAB ATIVE'S PHONE NUMBER: | | | |
| PRESCRIBER INFORMATION | ON | | | |
| LAST NAME: | | FIRST NAME: | FIRST NAME: | |
| PRESCRIBER SPECIALTY: | | EMAIL ADDRESS: | | |
| NPI NUMBER: | | DEA NUMBER: | | |
| PHONE NUMBER: | | FAX NUMBER: | | |
| STREET ADDRESS: | | | | |
| CITY: | | STATE: ZIP CC | DDE: | |
| REQUESTOR (if different than prescriber): | | OFFICE CONTACT PERSO | OFFICE CONTACT PERSON: | |
| | | | | |
| MEDICATION OR MEDIC | AL DISPENSING INFORMATIO | N | | |
| MEDICATION NAME: | | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/REFILLS: | QUANTITY: | |
| NEW THERAPY RENEWAL DURATION OF THERAPY (SPECIFIC DATES): | | IF RENEWAL: DATE THERAPY INITIATED: | | |
| Continued on next page. | | | | |

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 12.15.2022

CAT0173







Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST NAME: | | |
|---|---|---|--|
| 1. HAS THE PATIENT TRIED ANY OTHE | R MEDICATIONS FOR THIS CONDITION? | YES (if yes, complete below) NO | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: | |
| | | | |
| 2. LIST DIAGNOSES: | | ICD-10: | |
| ☐ Febrile neutropenia prevention☐ Hematopoietic Subsyndrome of Acu | te Radiation Syndrome | | |
| Trematopoletic Sabsyriarome of Aca | te Radiation Synarome | | |
| ☐ Other diagnosis: | ICD10 | | |
| 3. REQUIRED CLINICAL INFORMATION | I: PLEASE PROVIDE ALL RELEVANT CLINIC | L CAL INFORMATION TO SUPPORT A | |
| PRIOR AUTHORIZATION. | | | |
| patient? Yes No Does the patient have a diagnosis of a | ed to prevent febrile neutropenia in a p a non-myeloid malignancy and is the pa ence of febrile neutropenia of 20% or gro | tient receiving chemotherapy and/or | |
| Is the patient at an increased risk for reasons?* | developing chemotherapy-induced infe | ctions due to any of the following | |
| □ Pre-existing neutropenia (ANC of 2 | 1,000/mm³ or less) | | |
| □ Extensive prior exposure to chemo | otherapy | | |
| □ Previous exposure of pelvis or oth | er areas of large amounts of bone marr | ow to radiation | |
| ☐ History of recurrent febrile neutro | penia from chemotherapy | | |
| □ Patient is 65 years of age or older | | | |
| ☐ Patient has a condition that can po | otentially increase the risk of serious inf | ectin(I.e., HIV/AIDs) | |
| *Please submit documentation. | | | |
| Are there any other comments, diagnostician feels is important to this re | | ailed, and/or any other information the | |
| | | | |
| Please note: Not all drugs/diagnosis a information is received. | re covered on all plans. This request may | t be denied unless all required | |
| | | | |

 $\hbox{@ 2017-2023}$ by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 12.15.2022

CAT0173







Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



Revision Date: 12.15.2022

CAT0173



